A petitción popular abro este hilo de seguimiento. Por casualidad la observé y le hice una entrada para rebote siguiendo en AT. Perece que puede haber algo más ya que trabajan con una Orphan Drug (perdonad mi vocabulario no técnico). Estudios en Fase I si no me equivoco. Algunos compañeros me proponen que puede ser interesante y aqui lo dejo.
Orphan Drug. OTC. Centimos de $. Ingredientes para los que quieren adrenalina.
Anyone with an eye on Penny Stocks in recent weeks has seen the spectacular rise of Bio-Matrix Scientific Group, Inc. (OTC: BMSN) from triple zero 2's to recent highs of well over a Penny. As the stock continues to trade massive volume many investors are speculating this one goes way higher from current levels.
All the excitement is about HemaXellerate I™ BMSN's subsidiary Regen BioPharma new stem cell drug to combat Aplastic Anemia. The Company has submitted an Investigational New Drug (IND) Application to the FDA several weeks ago and things are looking on the up and up.
HemaXellerate I™ BMSN’s stem cell drug to combat Aplastic Anemia is eligible for Orphan Drug Status which makes HemaXellerate I™ able to get full FDA approval in as little as 60 days to bypass the lengthy Phase I, II, III, IV FDA Approval Processes because of being eligible for Orphan Drug Status.
Judging that the potential market share for the Companies new drugs are well over US $10 billion even if BMSN were able to achieve a small market share, this little biotechnology Company that trades on the bb's with a total market valuation of several million dollars could represent a spectacular trade opportunity for smart early investors.
Penny Stock Speculators should be warned however that stories as juicy as this one do come around quite often on the sub exchanges and most of the time it’s all fluff or outright lies and does not bode well for investors.
Conclusion: BMSN has made an explosive move up as investors wait un news from the Food and Drug Administration (FDA) While HemaXellerate I™ could mean huge gains for investors it could just as easily go nowhere and leave investors holding the bag.
If we look at its trading history of the past 52 weeks, the share price suffered a low of $0.02 on Dec 17, 2010 and was moved to the maximum level of $0.18 on Mar 15, 2010. Bio-Matrix Scientific Group, Inc. is a development stage company. The Company, through its wholly-owned subsidiary Regen BioPharma ,Inc., is engaged in the development of regenerative medical applications which it focuses to license from other entities up to the point of completion of Phase I and or Phase II.
Ayer subió un +24 con aumento de volumen. Puede que no sea el mejor dia para abrir el hilo, ya que puede corregir. Los cortos han aumentado. Esto favorece al que quiera entrar si le interesa.